KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2025)

Recursion Pharmaceuticals' Non-Current Assets history spans 6 years, with the latest figure at $661.3 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 9.95% year-over-year to $661.3 million; the TTM value through Dec 2025 reached $2.8 billion, up 91.35%, while the annual FY2025 figure was $661.3 million, 9.95% down from the prior year.
  • Non-Current Assets reached $661.3 million in Q4 2025 per RXRX's latest filing, down from $685.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $734.3 million in Q4 2024 to a low of $50.1 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $289.1 million, with a median of $214.9 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 240.66% in 2024, then dropped 9.95% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $75.6 million in 2021, then skyrocketed by 73.85% to $131.5 million in 2022, then soared by 63.96% to $215.6 million in 2023, then soared by 240.66% to $734.3 million in 2024, then decreased by 9.95% to $661.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Non-Current Assets are $661.3 million (Q4 2025), $685.4 million (Q3 2025), and $715.2 million (Q2 2025).